GeneDx Holdings Corp. (WGS)
| Market Cap | 3.02B -18.0% |
| Revenue (ttm) | 454.43M +25.4% |
| Net Income | -106.36M |
| EPS | -3.64 |
| Shares Out | 29.82M |
| PE Ratio | n/a |
| Forward PE | 148.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 786,139 |
| Open | 104.59 |
| Previous Close | 104.95 |
| Day's Range | 99.70 - 105.00 |
| 52-Week Range | 32.21 - 170.87 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 90.44 (-10.54%) |
| Earnings Date | Oct 27, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Financial Performance
In 2025, GeneDx Holdings's revenue was $427.54 million, an increase of 39.97% compared to the previous year's $305.45 million. Losses were -$21.02 million, -59.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $90.44, which is a decrease of -10.54% from the latest price.
News
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong Q2 growth was driven by core channels, with significant untapped potential remaining in geneticists, pediatric neurology, and NICU. Expansion into primary care and prenatal markets is underway, supported by new guidelines and operational improvements. Collection rates and gross margins are expected to rise as automation and payer-specific processes are implemented.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
Second quarter saw 32% volume growth and a return to adjusted profitability, driven by expanded policy coverage for whole genome sequencing. Efforts focus on improving collection rates, optimizing product mix, and leveraging new guidelines and commercial expansion to drive future revenue growth.
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
GeneDx Holdings Earnings Call Transcript: Q2 2026
Record Q2 volume and revenue exceeded guidance, with profitability achieved ahead of schedule. Strong demand and expanded payer coverage, especially for genome testing, set the stage for sustained growth, with significant improvements in collection rates and cash flow expected in late 2026 and 2027.
GeneDx Holdings Slides: Q2 2026
GeneDx Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
GeneDx Holdings Earnings release: Q2 2026
GeneDx Holdings released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
GeneDx Holdings Quarterly report: Q2 2026
GeneDx Holdings has published its Q2 2026 quarterly earnings report on August 3, 2026.
GeneDx Reports Second Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
Key Dates and Disclosure Events GeneDx Shareholders Need to Know: From $51 Million Acquisition Promise to $31.2 Million Write-Off in Just 12 Months NEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt al...
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026.
WGS Stockholders Have Rights – If You Lost Money Investing in GeneDx Holdings Corp. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is Investigating Allegations that GeneDx Holdings Corp. (WGS) Misled Investors Regarding the Positive Impact of the Fabric Genomics Acquisiti
GeneDx Holdings Transcript: AGM 2026
The meeting highlighted strong financial growth, FDA recognition, and strategic expansion into new markets. All four shareholder proposals passed with significant majorities, and no questions were raised during the Q&A session.
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
Investor Notice of Barrack, Rodos & Bacine Concerning Its Lawsuit Against GeneDx Holdings Corp. (WGS)
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos & Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock...
GENEDX HOLDINGS CORP. (WGS) INVESTOR ALERT Investors With Large Losses in GeneDe Holdings Corp. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of GeneDx Holdings Corp. (WGS)
Philadelphia, Pennsylvania--(Newsfile Corp. - June 10, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS).
GeneDx Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Expanding rare disease diagnostics beyond geneticists to pediatricians and NICUs, leveraging updated guidelines and AI-driven tools to simplify workflows and reporting. Strong market position is supported by a unique data set, rapid turnaround, and a focus on long-term genome adoption despite near-term margin pressures.
GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 20...
GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
PHILADELPHIA, May 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders who have lost mo...
GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ: WGS). The investigation focuses on GeneDx's ...